Medicare AdvantageCoverageMedium impact
MA08.073u, Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors
Independence Blue Cross·Ophthalmology·Pharmacy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage updated the medical necessity criteria for intravitreal injection of VEGF antagonists, VEGF biosimilars, and combination VEGF/Angiopoietin-2 inhibitors. This affects coverage requirements for eye injection treatments commonly used for conditions like macular degeneration and diabetic retinopathy.
Action Required
Before January 1, 2026: Billing team and ophthalmology providers must review and update documentation requirements for intravitreal VEGF injections to meet new medical necessity criteria. Update prior authorization processes and ensure clinical documentation aligns with revised Medicare Advantage requirements to prevent claim denials.